NASDAQ$AMGN

Amgen Inc · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Amgen reported Q1 2025 revenue of $8.15B with net income of $1.73B and diluted EPS of $3.20.

Total revenue was $8.15 billion as key brands and recent acquisitions contributed. Net income was $1.73 billion, or $3.20 per diluted share, with R&D and integration costs discussed in MD&A.

  • Q1 revenue $8.15B.
  • Net income $1.73B; diluted EPS $3.20.
  • Product sales mix across rare disease and oncology.
  • Horizon integration and pipeline investments.

Headline financials

Total Revenue

$8.15B

Previous: $7.45B+9.4%
EPS (adj)

$3.20

Previous: $3.96-19.2%
Free Cash Flow

$980M

No prior period
Avg Diluted Shares (M)

541

No prior period
Capital Expenditures

-$411M

Previous: -$230M-78.7%
Net Income

$1.73B

Previous: -$113M+1631.0%
Operating Income

$1.18B

Previous: $991M+18.9%
Gross Profit

$6.73B

Previous: $4.25B+58.4%
R&D Expense

$1.48B

Previous: $1.32B+12.0%

Revenue & EPS history

Amgen · Revenue · Quarterly

$8.15B

Q1 2025+9.4%vs Q1 2024
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Amgen · $6.14B total across 17 segments · Q3 2023

  • Enbrel
    $1.04B-6.4%
  • Prolia
    $986M+14.4%
  • Otezla
    $567M-9.6%
  • XGEVA
    $519M+4.8%
  • Nplate
    $419M+45.5%
  • Repatha
    $406M+31.4%
  • KYPROLIS
    $349M+9.7%
  • Aranesp
    $323M-9.8%
  • EVENITY
    $307M+52.7%
  • Vectibix
    $252M+2.0%
  • BLINCYTO
    $220M+54.9%
  • MVASI
    $213M+1.9%
  • Other products
    $167M+46.5%
  • TEZSPIRE
    $161M+192.7%
  • Neulasta
    $124M-49.8%
  • LUMAKRAS/LUMYKRAS
    $52M-30.7%
  • TAVNEOS
    $37M

Forward guidance

Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.

Tailwinds

  • Headline results and segment trends anchor the quarter.
  • Liquidity and balance-sheet capacity support operations.
  • Strategic initiatives outlined in MD&A.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items affect year-over-year comparability.
  • Execution risk on growth or restructuring plans.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+0.3%

Avg return

Earnings day

+0.0%

Avg return

5 days after

+0.1%

Avg return

30 days after

53%

39 / 73 earnings

Positive

+12.2%

Q1 2024

Best reaction

-8.7%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.9%-4.4%-2.7%
Q4 2025+3.0%+11.0%+9.1%
Q3 2025+7.7%+9.1%+11.2%
Q2 2025-5.1%-5.0%-5.5%
Q1 2025-1.1%-2.8%+1.6%
Q4 2024+6.5%+2.0%+12.4%
Q3 2024+1.3%+0.3%-10.5%
Q2 2024-3.9%-0.8%-0.3%
Q1 2024+12.2%+8.3%+10.3%
Q4 2023-8.1%-9.6%-15.3%
Q3 2023-0.9%+2.5%+2.5%
Q2 2023+5.6%+13.2%+11.4%
Q1 2023+0.4%-1.2%-9.2%
Q4 2022-2.1%-2.6%-6.7%
Q3 2022+0.0%+8.7%+6.1%
Q2 2022-0.4%+0.5%-1.9%
Q1 2022-4.7%-7.6%+2.2%
Q4 2021+8.5%+2.7%+4.2%
Q3 2021+4.0%+1.9%-4.1%
Q2 2021-4.8%-4.0%-5.8%
Q1 2021-7.4%-6.2%-7.9%
Q4 2020-1.4%-1.7%-7.7%
Q3 2020-2.5%-1.5%+0.6%
Q2 2020-1.9%-3.5%-0.3%
Q1 2020-2.0%+0.3%-2.5%
Q4 2019-4.9%-2.4%-12.1%
Q3 2019+2.9%+6.3%+14.4%
Q2 2019+6.0%+6.3%+17.5%
Q1 2019-2.8%-2.1%-6.7%
Q4 2018-3.7%-2.5%-1.0%
Q3 2018+2.4%-0.6%+7.5%
Q2 2018-0.3%+1.8%+1.9%
Q1 2018+0.1%+1.6%+1.9%
Q4 2017+0.5%-5.1%-0.5%
Q3 2017-2.1%-3.2%-5.7%
Q2 2017-2.9%-3.6%-6.1%
Q1 2017-1.2%-1.3%-5.9%
Q4 2016+4.9%+4.5%+12.9%
Q3 2016-8.7%-11.5%-8.5%
Q2 2016+2.2%+3.9%+2.6%
Q1 2016-1.7%
Q4 2015+1.5%
Q3 2015-0.9%
Q2 2015+3.0%
Q1 2015+1.9%
Q4 2014-3.2%
Q3 2014+6.7%
Q2 2014+6.0%
Q1 2014-3.2%
Q4 2013+0.5%
Q3 2013+1.8%
Q2 2013-1.0%
Q1 2013-7.5%
Q4 2012-0.8%
Q3 2012+0.8%
Q2 2012+7.6%
Q1 2012+0.2%
Q4 2011-0.8%
Q3 2011+4.9%
Q2 2011-3.0%
Q1 2011-1.5%
Q4 2007+0.7%
Q4 2010+0.7%
Q3 2008+0.7%
Q3 2010-0.9%
Q2 2010-0.4%
Q1 2009+1.5%
Q1 2010+1.2%
Q4 2009+0.5%
Q3 2009+1.6%
Q4 2008+3.8%
Q2 2009+3.8%
Q2 2008+3.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro